Close Menu

You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.

Home » Business, Policy & Funding » Regulatory News & FDA Approvals » FDA Approves AstraZeneca's Lynparza, Myriad Genetics' CDx for BRCA-Positive Pancreatic Cancer

FDA Approves AstraZeneca's Lynparza, Myriad Genetics' CDx for BRCA-Positive Pancreatic Cancer

Dec 30, 2019
|
staff reporter

NEW YORK – The US Food and Drug Administration expanded the indication for AstraZeneca and Merck's olaparib (Lynparza) as a maintenance treatment for certain metastatic pancreatic cancer patients identified with the help of a companion diagnostic, the two drugmakers announced on Monday.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Scan

Even Bigger

Politico reports that the NYPD DNA database has grown since it announced it would be removing profiles from it.

Got Into the Lab Machines

Forbes reports that a structural biology lab at Oxford University studying the coronavirus was hacked.

Not Going to Pay

Science reports that a Dutch research funding agency is combating a ransomware attack.

Science Papers Present Haplotype-Resolved Genomes, MiRNA-Linked Complex Tied to Ribosomal Protein Production

In Science this week: set of 64 haplotype assemblies from 32 individuals, and more.

What's Popular?

In Regulatory News & FDA Approvals

  1. Novacyt Obtains CE Mark for Extraction-Free COVID-19 PCR Test

  2. GenDx HLA Genotyping Products Receives Health Canada IVD Approval

  3. FDA Issues New Guidance on SARS-CoV-2 Variants for Test Developers

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2021 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.